Pomalidomide has clear efficacy in the treatment of multiple myeloma and Kaposi sarcoma, but is also associated with various adverse reactions.
I. Common side effects of pomalidomide
1. Hematologic toxicity
(1) Neutropenia is the most common grade 3/4 adverse reaction, occurring in approximately 46% of patients.
(2) Anemia and thrombocytopenia are also common, accounting for about 42% and 23%, respectively.
(3) Febrile neutropenia occurs in about 8% of patients.
(4) In patients with Kaposi sarcoma, the incidence of neutropenia is as high as 96% (grade 3/4 in 50%).
2. Constitutional symptoms
(1) Fatigue and weakness are most prominent, occurring in about 63% of patients.
(2) Fever, peripheral edema, and chills are also common.
(3) Fatigue occurs in about 68% of patients with Kaposi sarcoma.
3. Gastrointestinal reactions
(1) Constipation and diarrhea each occur in about 37% of patients, nausea in about 24-36%.
(2) In patients with Kaposi sarcoma, constipation occurs in 71%, nausea in 36%, and diarrhea in 32%.
4. Respiratory symptoms
Dyspnea occurs in about 45% of patients, cough in about 22%, and upper respiratory tract infection in about 29%.
5. Neuropsychiatric system
Peripheral neuropathy in about 18%, dizziness in about 14%, confusional state in about 7-13%.
6. Skin reactions
(1) Rash in about 16-21%, pruritus in about 9-15%, hyperhidrosis in about 16%.
(2) Be alert for severe skin reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis.
7. Other important adverse reactions
Venous and arterial thromboembolism (deep vein thrombosis 4.7%, myocardial infarction and stroke about 3%), liver function impairment (elevated liver enzymes, liver failure), tumor lysis syndrome, second primary malignancies (acute myeloid leukemia), etc.
II. Ways and means to alleviate side effects
1. Management of hematologic toxicity
Monitor complete blood count weekly for the first 8 weeks of treatment, then monthly thereafter.
2. Prevention of thromboembolism
(1) Patients with risk factors for thrombosis should receive antithrombotic prophylaxis.
(2) Inform patients to seek immediate medical attention if they experience symptoms of thrombosis such as shortness of breath, chest pain, limb swelling, sudden numbness, or severe headache.
3. Monitoring of liver function impairment
(1) Monitor liver function monthly. If elevated liver enzymes occur, interrupt pomalidomide for evaluation, and consider resuming treatment at a lower dose after recovery to baseline.
(2) Patients should report symptoms such as jaundice, dark urine, or right upper quadrant pain promptly.
4. Management of severe skin reactions
(1) Consider interrupting or discontinuing pomalidomide for grade 2-3 rash.
(2) Permanently discontinue pomalidomide if grade 4 rash, exfoliative or bullous rash, or confirmed Stevens-Johnson syndrome, toxic epidermal necrolysis, or DRESS syndrome occurs.
5. Management of neurological symptoms
(1) Avoid activities requiring high alertness (e.g., driving).
(2) Patients with dizziness and confusional state should not add other medications that may worsen these symptoms on their own.
6. Supportive care measures
(1) For severe anemia, red blood cell transfusion or erythropoietin may be used.
(2) Febrile neutropenia requires broad-spectrum antibiotics.
(3) Nausea, diarrhea, and constipation can be managed symptomatically with antiemetics, antidiarrheals, and laxatives.
III. Storage conditions for pomalidomide
1. Temperature requirements
Store at room temperature between 20°C and 25°C, with brief excursions permitted between 15°C and 30°C.
2. Handling precautions
(1) Capsules should be swallowed whole, not opened, crushed, or chewed.
(2) If accidental contact with powder from a broken capsule occurs, wash the skin thoroughly with soap and water.
(3) If powder contacts mucous membranes, rinse with copious amounts of water.
3. Child safety
Keep the medication out of the reach of children.
